Seventure Partners

Founded in 2016, Reelevant specializes in enhancing customer experiences by delivering personalized content across digital platforms. It achieves this by analyzing real-time data to synchronize relevant brand moments with each customer's current life stage, thereby maximizing customer lifetime value for clients such as Carrefour, Décathlon, and L'Oréal.

Flexvelop is a fintech company based in Hamburg that specializes in providing an embedded payment solution for financing business equipment. By enabling business customers to rent new equipment that is fully insured, Flexvelop allows for the flexibility to either purchase or return the equipment at any time. This approach offers a swift and adaptable alternative to traditional leasing processes, utilizing patented in-house financing technology. Flexvelop's services are designed to support startups and medium-sized enterprises by facilitating the acquisition of equipment from various suppliers quickly and efficiently. In addition to enhancing operational capabilities, Flexvelop promotes a sustainable circular economy by encouraging the use of the latest technology while minimizing waste.

SeaWeed Concept is a marine biotechnology company that specializes in harnessing the potential of seaweed to supply high-quality, sustainable ingredients to diverse industries. The company's patented preservation technologies allow seaweed to be stored for extended periods, ensuring a consistent, year-round supply for sectors such as food, cosmetics, and agriculture.

Ekstere is an online marketplace that specializes in the sale of pre-owned electric bicycles. The company offers a curated selection of reconditioned e-bikes that come with certification, ensuring quality and reliability for consumers. By prioritizing sustainability and transparency, Ekstere enables customers to purchase electric bicycles at reasonable prices, thereby promoting the adoption of eco-friendly transportation solutions. The platform targets consumers who value verified quality and seeks to make electric mobility accessible to a broader audience.

Anybuddy is a French-based sports booking platform specializing in racket sports. It facilitates match arrangements for football or tennis, offering users access to various sports facilities and payment options through its user-friendly application.

Karmen provides non-dilutive financing solutions tailored for digital businesses. Its platform facilitates swift access to capital for various operational needs such as customer acquisition, recruitment, and inventory financing.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.

Founded in 2019, Syroco is an innovation lab based in Marseille, France. It operates a scientific laboratory focused on improving energy and transportation industries' systemic efficiency through 'moonshot challenges'. The company designs and develops cutting-edge technologies to achieve extreme challenges, such as creating a speed craft for sailing records.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Dashbook is a publishing house that facilitates collaborative book creation and distribution. It empowers authors by providing a platform to publish their works, making them accessible to the public.

Siit offers an AI-powered service desk platform designed for IT and internal operations teams. The solution integrates with existing communication channels, automates manual tasks, and provides advanced analytics to enhance employee experience, improve operational efficiency, and reduce support costs.

Otoqi develops an automotive management platform that streamlines vehicle logistics throughout their lifecycle. Its solutions include delivery services, concierge transfers between sites, fleet management, and more, enabling dealerships to enhance operational efficiency, improve customer satisfaction, and drive sales growth.

A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform that focuses on studying the marine environment, integrating advanced technologies to enhance maritime activities. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By enabling maritime industries to manage increasing volumes of data and conduct complex analyses, Sinay supports stakeholders in making informed decisions and improving efficiency within the sector.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

ID5 is a company focused on enhancing online advertising for consumers, media owners, and advertisers, with a primary aim of helping publishers achieve sustainable revenue growth. It offers a transparent and privacy-compliant identity infrastructure that replaces third-party cookies and mobile advertising IDs. This infrastructure improves user recognition and match rates, providing a stable, consented, and encrypted user ID. By doing so, ID5 enables publishers to better monetize their audiences and allows advertisers to execute effective and measurable campaigns. Additionally, the company's centralized identification synchronization platform addresses inefficiencies in website campaign performance by managing cookie synchronization, ensuring privacy compliance, and optimizing consent management, thus enhancing the overall user experience and operational efficiency for publishers and data providers.

Peptobiotics is a biotechnology startup focused on livestock disease prevention through innovative synthetic biology solutions. The company specializes in the development of recombinant custom peptides cultivated from synthetic microorganisms, which serve as antibiotic alternatives for promoting animal health and growth. By providing farmers and breeders with effective tools to protect livestock against pathogens, Peptobiotics aims to enhance agricultural productivity while ensuring humane and sustainable practices. The company’s approach addresses the critical need for disease prevention in livestock without contributing to antibiotic resistance, thereby fostering a more responsible and sustainable agricultural ecosystem.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Starfish Bioscience specializes in developing biotechnological systems for agriculture and viticulture. Its primary focus is regenerating soil health by restoring microbiomes, enhancing sustainability and crop yields, while minimizing environmental impact.

Nimble Science Ltd. is a digital health company focused on revolutionizing gastrointestinal (GI) health through its innovative SIMBA capsule technology. This end-to-end platform facilitates multi-omic mapping of the GI tract, allowing for the passive sampling of small bowel luminal fluid. By leveraging this advanced sampling method, Nimble Science provides precision datasets that offer valuable insights into GI health, thereby transforming the diagnosis and treatment of gastrointestinal conditions. The company's approach enables healthcare providers to directly sample and analyze targeted regions of the GI tract, marking a significant advancement in the understanding and management of GI health.

Founded in 2006, Nexess specializes in developing and selling advanced security management solutions for nuclear and high-risk industrial plants. Its product portfolio includes RFID tags, smart cameras, antenna systems, and software platforms designed to enhance traceability, productivity, and security. Headquartered in Mougins, France, with an additional office in Paris, the company serves clients aiming to improve their operational efficiency and safety.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Pitchy is a video creation platform that offers a software-as-a-service (SaaS) solution for users to produce professional interactive videos without needing technical skills. By utilizing ready-to-use templates designed with Adobe After Effects, users can easily customize videos for various scenarios, such as investor pitches or product descriptions. The platform allows users to create videos by simply selecting a template, adding their own text, images, logos, and videos, and completing the project in minutes. Clients have the option to either purchase the final video or subscribe for a monthly fee, which includes hosting the video on Pitchy's own account. With its focus on user-friendly design and efficient video production, Pitchy aims to help businesses enhance their marketing efforts and drive customer engagement.

Allozymes is a pioneering company specializing in advanced microfluidics technology. It accelerates enzyme evolution and development by creating sensitive assays for detecting enzymatic reactions, proprietary microfluidic chips, and proteomics technologies.

Hepster is an InsurTech company specializing in customized digital insurance solutions. It offers a range of products including bikes, electronics, sports equipment, and other specialty insurances, tailored to both B2B partners and consumers via its webshop.

Sekoia.io is a developer of an advanced security operations center (SOC) platform that equips security teams with tools to effectively identify and respond to significant cyber threats across their entire attack surface. The platform integrates real-time detection and automation, allowing teams to manage the complexities and high volumes of security incidents while reducing false positives. By continuously analyzing emerging threats and implementing strategic responses, Sekoia.io enables organizations to enhance their security posture and respond to threats more swiftly and reliably than traditional security information and event management (SIEM) systems. This proactive approach ensures that clients remain informed and prepared against evolving cyber risks.

Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform that focuses on studying the marine environment, integrating advanced technologies to enhance maritime activities. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By enabling maritime industries to manage increasing volumes of data and conduct complex analyses, Sinay supports stakeholders in making informed decisions and improving efficiency within the sector.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.

Graphite Innovation & Technologies develops sustainable marine coatings for ships by applying nanotechnology to create durable, environmentally friendly paints that reduce fuel consumption and greenhouse gas emissions. The company’s marine coating systems are designed to be hydrophobic and hard, discouraging marine growth and minimizing hull drag as vessels pass through water. Its solutions aim to deliver peak vessel efficiency while avoiding harmful leaching substances common in traditional coatings. In addition to coatings for seafaring vessels, the company explores advanced engineered materials based on graphene and related nanomaterials to lower production costs and enable customized performances aligned with customers’ sustainability objectives. With existing ocean-going ships utilizing its technology, Graphite Innovation & Technologies seeks to ramp production worldwide and position itself as a disruptor in the marine coatings market by combining high-performance materials with environmentally responsible formulations.

Glopal is a leading ecommerce platform that empowers businesses to expand internationally. It offers comprehensive tools for localization, marketing, international shipping, and duties & taxes calculation, enabling companies to attract, convert, and delight customers worldwide.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Flexvelop is a fintech company based in Hamburg that specializes in providing an embedded payment solution for financing business equipment. By enabling business customers to rent new equipment that is fully insured, Flexvelop allows for the flexibility to either purchase or return the equipment at any time. This approach offers a swift and adaptable alternative to traditional leasing processes, utilizing patented in-house financing technology. Flexvelop's services are designed to support startups and medium-sized enterprises by facilitating the acquisition of equipment from various suppliers quickly and efficiently. In addition to enhancing operational capabilities, Flexvelop promotes a sustainable circular economy by encouraging the use of the latest technology while minimizing waste.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Founded in 2011, Mediarithmics operates a cloud-based data marketing platform headquartered in Fontenay-sous-Bois, France. The company enables brands to manage retargeting campaigns across multiple devices and allows agencies to handle clients' RTB and email campaigns through a single tool.

BAOUW / Outdoor Organic Nutrition specializes in the production of organic food products designed for athletes and health-conscious individuals. The company offers a range of items, including organic nutrition bars, purees, energy nuts, and various accessories. Emphasizing natural ingredients, BAOUW focuses on unprocessed components that provide beneficial lipids, vegan proteins, and natural fruit sugar. Their products are formulated to deliver long-lasting energy while being easy to digest and convenient for on-the-go consumption. Through their commitment to gourmet, responsible, and efficient nutrition, BAOUW aims to support individuals in maintaining their health and performance.

Citalid is a cybersecurity company that specializes in assessing and quantifying cyber risks for enterprises and insurers. The company has developed an advanced platform that evaluates the likelihood of cyberattacks and estimates their potential financial impacts. By integrating Cyber Threat Intelligence with risk quantification, Citalid offers a comprehensive view of potential threats and simulates various scenarios to model their financial consequences. This enables organizations to make informed decisions about their cybersecurity strategies and prepare effectively. Additionally, Citalid provides tailored security and insurance recommendations, helping businesses implement actionable measures to mitigate risks. For insurers, the platform enhances the understanding of portfolio exposure to cyber threats and supports customers in making smarter decisions regarding cyber risk management.

Clinical Microbiomics is an independent contract research organization dedicated to advancing microbiome research across various domains, including human, animal, plant, and soil microbiomes. The company offers comprehensive microbiome research services, which encompass clinical trial consulting, sequencing, and complex bioinformatics. With a team of skilled molecular biologists and bioinformatics specialists, Clinical Microbiomics focuses on the role of the microbiome in various clinical conditions such as diabetes, obesity, and inflammatory bowel diseases. Their approach emphasizes collaboration, ensuring that microbiome experts guide partners through the study process, from experimental design to final analysis. By thoroughly reviewing findings with clients, Clinical Microbiomics aims to provide actionable insights that enhance research outcomes and promote the application of microbiomes in treating diseases and improving agricultural practices.

Soan is an online payment solution that provides a comprehensive suite of tools designed to facilitate the success of freelance projects. The company's platform enables users to manage their finances effectively, offering features such as an integrated payment system for invoicing, automated bill reminders, and other financial management tools. By streamlining these processes, Soan supports businesses in maintaining better control over their financial operations and enhancing their overall productivity.

Standing Ovation specializes in developing vegan cheese alternatives that closely mimic the taste and texture of traditional dairy cheese. The company employs scientific methods to create animal-free and environmentally friendly cheese products, utilizing protein-producing microbes that are fed with plant-based sugars in a fermentation process reminiscent of traditional cheesemaking. This innovative approach not only offers a healthier option for consumers but also aligns with the growing demand for sustainable and plant-based food choices.

Sentryc is a brand protection software company that provides a software-as-a-service platform to detect and stop product piracy and brand abuse on online marketplaces. The platform automates monitoring of products across websites and social channels, detects counterfeits and trademark infringements, traces unauthorized dealers, and supports documentation and reporting to enable removal of infringing listings. The company was founded in 2019 and is headquartered in Berlin, with offices in Barcelona and Stettin.

Ideel is a platform that centralizes household expenses and subscriptions, enabling users to view all costs in one place and receive alerts for tariff changes, renewals, or end of trial periods. It allows canceling or pausing subscriptions with a click and automates related steps within the interface, reducing administrative tasks. By consolidating invoices and offering optimization tools and important update notices, Ideel helps users manage finances more efficiently, potentially lower expenses, and maintain better control over services without switching between sites or apps.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Jolimoi is a skincare and beauty company offering a catalog of face care, hair care, makeup, oils, fragrances and related accessories for men and women, and it provides personalized product recommendations based on customers' preferences.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Geovelo is a company that develops a free navigation application designed to assist cyclists with route planning and guidance. The app provides directions through voice prompts, maps, or compass features, helping users discover rides, plan trips, and find reliable and secure routes. Additionally, it fosters community engagement by allowing users to join groups and participate in challenges, thereby promoting daily cycling.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Hepster is an InsurTech company specializing in customized digital insurance solutions. It offers a range of products including bikes, electronics, sports equipment, and other specialty insurances, tailored to both B2B partners and consumers via its webshop.

Founded in Paris, France in 2014, HARDLOOP is an online retailer specializing in sports products. It offers a wide range of items including shoes, gloves, bottles, and other accessories for various adventure sports such as hiking, running, skiing, climbing, and swimming.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Ecto, established in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, specializes in developing advanced technology that intersects data and biology to enhance aquaculture efficiency and sustainability globally. Headquartered in Boston with offices in Atlanta and Stavanger, Norway, the company collaborates with farmers worldwide, offering a farm management platform that integrates operational data with molecular biology. This enables real-time insights, disease detection, and prevention, ultimately streamlining production processes and creating healthier protein servings. To date, Ecto's solutions have facilitated an additional 51.5 million healthy servings of protein. The company has been backed by competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.

CattleEye, founded in 2019 in the United States, specializes in manufacturing autonomous livestock monitoring systems. The company offers a cloud-based artificial intelligence platform that interprets and analyzes visual imagery of livestock using web cameras and other vision detection equipment. This solution identifies and measures various indicators such as gait, mobility scores, and other behavioral signs, providing farmers with comprehensive insights into the performance and welfare of their cows.

Proteon Pharmaceuticals Ltd. is a biotechnology company based in Lodz, Poland, founded in 2005. The company specializes in developing bacteriophage-based products aimed at enhancing animal and human health while promoting environmental sustainability. Proteon Pharmaceuticals employs precision biology to create solutions that protect the microbiome, significantly reducing the reliance on antibiotics and addressing the challenges posed by antimicrobial resistance. Their product pipeline includes innovative applications for poultry, aquaculture, and dairy sectors, focusing on improving performance, food safety, and preventing economically significant bacterial diseases. Additionally, the company offers contract services for high-throughput screening of chemical libraries, as well as ADME/Tox and immunotoxicity testing of therapeutic substances using in vitro cell cultures.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Ecto, established in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, specializes in developing advanced technology that intersects data and biology to enhance aquaculture efficiency and sustainability globally. Headquartered in Boston with offices in Atlanta and Stavanger, Norway, the company collaborates with farmers worldwide, offering a farm management platform that integrates operational data with molecular biology. This enables real-time insights, disease detection, and prevention, ultimately streamlining production processes and creating healthier protein servings. To date, Ecto's solutions have facilitated an additional 51.5 million healthy servings of protein. The company has been backed by competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.

Otoqi develops an automotive management platform that streamlines vehicle logistics throughout their lifecycle. Its solutions include delivery services, concierge transfers between sites, fleet management, and more, enabling dealerships to enhance operational efficiency, improve customer satisfaction, and drive sales growth.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

SportEasy is a web and mobile platform that helps amateur sports teams manage their activities. It enables coaches and managers to organize games and practices, coordinate communication with players, and track team statistics and insights. The application includes social features that let players share updates and engage with teammates, while reducing administrative tasks for mentors, coaches, volunteers, and players so they can focus more on the field. The service is available on web and mobile devices and supports multiple languages. Launched in France in 2011, SportEasy targets grassroots sports environments through an integrated scheduling, messaging, and data-capture solution.

Cytoki Pharma ApS is a biotechnology company based in Værløse, Denmark, founded in 2019. The company is focused on developing innovative treatments for diseases with significant unmet medical needs, particularly those related to epithelial injuries. As a pre-clinical entity, Cytoki Pharma's lead program centers on an engineered long-acting IL-22 protein, which has been licensed from a major pharmaceutical company. IL-22 plays a crucial role in the immune response, acting as a signal for tissue survival and repair following injury. By harnessing the therapeutic potential of this cytokine, Cytoki Pharma aims to create effective solutions for organ injuries and improve patient outcomes in conditions that currently lack adequate treatment options.

Expensya is a Paris-based provider of expense management software that automates professional expense reports across web and mobile platforms. The Expensya platform handles expense capture and processing, approval workflows, data export, accountant integration, archiving, email processing, mileage tracking, cost accounting, and scanning, with analytics. It runs on cloud and uses AI, machine learning, big data, and business intelligence to streamline operations. The solution is available in multiple languages and adapts to local accounting rules in roughly fifty countries. The company was founded in 2014 and is headquartered in Paris, France.

PEP-Therapy is a biotechnology company specializing in the development of innovative peptide-based therapies aimed at treating severe diseases, with a primary emphasis on cancer. The company focuses on creating Cell Penetrating and Interfering Peptides, which are designed for intracellular delivery of targeted treatments. These peptides effectively penetrate cell membranes to block crucial intracellular protein-protein interactions, thereby inhibiting important pathogenic mechanisms associated with various diseases. By harnessing the potential of these active compounds, PEP-Therapy aims to advance therapeutic options in oncology and beyond.

Foodsmart is a digital nutrition platform focused on enhancing health outcomes through personalized dietary recommendations. The company aims to support individuals dealing with chronic diseases and food insecurity by collaborating with health plans and healthcare providers. Its online telehealth application offers real-time guidance across various settings, including homes, workplaces, grocery stores, and restaurants. This comprehensive approach enables users to make healthier food choices and select recipes that can mitigate chronic health issues, thereby promoting overall well-being. By providing access to affordable and tailored healthy eating options, Foodsmart strives to empower individuals to improve their nutrition and health.

Hepster is an InsurTech company specializing in customized digital insurance solutions. It offers a range of products including bikes, electronics, sports equipment, and other specialty insurances, tailored to both B2B partners and consumers via its webshop.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Wealthpilot GmbH is a Munich-based company founded in 2017 that specializes in providing an online platform designed for investment advisors. The company aims to democratize wealth management, allowing individuals to take control of their financial lives and achieve their financial goals. Wealthpilot combines user-friendly technology with professional personal advice across a range of financial assets. Its Software-as-a-Service platform facilitates the automatic analysis and planning of various asset types, enabling advisors to offer data-driven, personalized wealth management services. By leveraging efficient cloud-based software, Wealthpilot enhances the capabilities of asset managers, streamlining processes and significantly reducing the time required to manage client assets effectively.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Dermala develops personalized treatments for chronic skin diseases using microbiome science. It offers FOBO Kit, pre-medicated pads, and an app for tracking treatment outcomes. Its products target acne, eczema, and aging by reducing oiliness, killing bad bacteria, and promoting good bacteria growth.

Animab is a biotechnology company focused on improving animal health through proprietary monoclonal antibody technology. It specializes in creating products that enhance intestinal health in livestock, particularly piglets during the critical post-weaning phase. Animab's antibodies mimic natural protective mechanisms to safeguard animals without disrupting their microbiome.

Federation Bio Inc., established in 2018 and headquartered in South San Francisco, California, specializes in the development of microbial therapeutics targeting diseases where the human microbiome holds curative potential. The company's platforms focus on secondary hyperoxaluria and explore treatments for metabolic disorders, immune diseases, and cancer. Federation Bio's approach involves leveraging naturally occurring or engineered bacteria alongside a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses.

LARQ, Inc. is a company that manufactures and sells self-cleaning water bottles and water purification systems. Founded in 2017 and based in Foster City, California, LARQ utilizes advanced UV-C LED technology to eliminate bio-contaminants, including germs, bacteria, and protozoa, from both the water and the bottle itself. This innovative approach not only ensures safe drinking water but also promotes sustainability and convenience for users. The company's products are available for purchase online, making it easier for individuals to access pristine drinking water wherever they may be.

Galecto is a clinical-stage biotechnology company developing small molecule therapeutics targeting galectin-3 and lysyl oxidase-like 2 for treating severe diseases like fibrosis and cancer. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for treating severe fibrotic lung diseases such as idiopathic pulmonary fibrosis.

Clim8 is a wearable technology company focused on personalized thermoregulation in smart clothing. It combines textile and digital technologies to monitor wearers’ body temperature with embedded sensors and a detachable battery pack, analyzes the data, and activates heating or cooling to meet individual comfort preferences in varying climates. The patented system integrates the thermal layer with a sensor suite to deliver automated temperature control through digital automation.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

TransferGo is a global money transfer company that enables individuals and businesses to send money internationally through a digital account-to-account platform. Headquartered in London, it offers online transfers with same-day delivery to selected destinations and aims to provide economical rates compared with banks and cash bureaus. The service targets migrant workers sending funds home and businesses paying suppliers, charging a fixed transfer fee and a currency conversion margin per transaction.

Saagie is a company specializing in big data analytics, focusing on DataOps Orchestration to streamline and expedite analytic projects. Its platform unifies people, processes, and technology, allowing organizations to transform raw data into actionable insights within weeks. Saagie's approach emphasizes rapid time-to-value and is designed to be open, featuring isolated containers and robust network engineering. The company prioritizes security and governance, ensuring trust, privacy, and traceability in analytic projects. Saagie's platform integrates seamlessly with both open-source and commercial technologies, catering to a variety of Big Data, AI, and analytics use cases. By providing a Plug and Play Orchestrator for DataOps, Saagie empowers businesses to leverage artificial intelligence and big data effectively, enhancing their competitive edge across diverse industries.

MycoTechnology is a food technology company based in Aurora, Colorado, that specializes in utilizing fungi-based food-processing platforms to enhance the flavor and nutritional value of agricultural products. Incorporated in 2013, the company addresses challenges in the food, beverage, and flavor industries through innovative solutions. One of its key products, ClearTaste, is an all-natural, GMO-free, organic bitter blocker that is both Kosher and Halal certified, designed to improve the flavor profile of various agricultural offerings. Additionally, MycoTechnology engages in the fermentation of agricultural products using gourmet fungi, producing items such as myceliated chocolate and enhanced coffee beans. The company also develops and licenses technology aimed at naturally improving the flavor characteristics of robusta and arabica coffee, thereby enabling food producers to incorporate healthier ingredients and strengthen brand association.

ViroVet is an innovative company focused on developing advanced technologies to combat viral diseases in livestock. Its product pipeline includes antiviral drugs targeting respiratory disease complexes and novel vaccines for swine viral infections. Given the substantial economic impact of viral diseases, which cost the livestock industry billions annually, ViroVet aims to provide effective solutions that can be used independently or alongside existing vaccines and biosecurity measures. The company addresses the growing demand for animal protein amid increasing global population and livestock density, as well as climate change challenges that heighten the risk of viral outbreaks. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to transform the industry, notably by reducing antibiotic usage and enhancing overall animal health and productivity.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

MOVE 'N SEE provides digital tools and an auto-follow camera for individual sports, team sports, and arena use. It provides attentive customer service, technological excellence, and an insatiable passion for sports, theater, and video.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

NovoBind is an integrated animal health company focused on developing next-generation biologics to address significant pathogens that impact food safety and livestock production. By targeting specific bacteria, viruses, and parasites that lead to intestinal ailments in livestock, aquaculture, and pets, NovoBind aims to combat the growing resistance to traditional anti-infectives and reduce harmful environmental residues. The company's innovative solutions are designed to mitigate the production losses exceeding $1 billion annually caused by these pathogens, thereby enhancing efficiency and sustainability in the animal sector.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Founded in Paris, France in 2014, HARDLOOP is an online retailer specializing in sports products. It offers a wide range of items including shoes, gloves, bottles, and other accessories for various adventure sports such as hiking, running, skiing, climbing, and swimming.

Founded in 2016, TIBOT Technologies designs and develops robots to enhance poultry farming. Its flagship products include Spoutnic, an assistant robot, and Spoutnic NAV, a robot for scrape, drink, and feed tasks. The company aims to improve animal welfare and profitability while easing the workload of farmers.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.